Colorectal Cancer Clinical Trial
Official title:
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
Verified date | March 2024 |
Source | Incyte Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC)
Status | Completed |
Enrollment | 54 |
Est. completion date | February 22, 2024 |
Est. primary completion date | February 22, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Ability to comprehend and willingness to sign an ICF. - Willing and able to conform to and comply with all Protocol requirements. - Histologically or cytologically confirmed advanced/metastatic SCCHN, NSCLC, ovarian cancer, TNBC, CRPC, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC) that progressed after treatment with available therapies (including anti PD-(L)1 therapy (if applicable). - Willingness to undergo pre- and on-treatment tumor biopsy. - Have CD8 T-cell-positive tumors. - Presence of measurable disease according to RECIST v1.1. - ECOG performance status 0 to 1. - Life expectancy > 12 weeks. - Willingness to avoid pregnancy or fathering children based. - Acceptable laboratory parameters Exclusion Criteria: - Clinically significant cardiac disease. - Known or active CNS metastases and/or carcinomatous meningitis. - Active or inactive autoimmune disease or syndrome that required systemic treatment in the past 2 years or receiving systemic therapy for an autoimmune or inflammatory disease.. - Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses > 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment. - Known additional malignancy that is progressing or requires active treatment,or history of other malignancy within 2 years of the first dose of study treatment. - Has not recovered to = Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study treatment. - Evidence of interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis. - Immune-related toxicity during prior immune therapy for which permanent discontinuation of therapy is recommended, or any immune-related toxicity requiring intensive or prolonged immunosuppression to manage. - Any prior chemotherapy, biological therapy, or targeted therapy to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment. - Any prior radiation therapy within 28 days before the first dose of study treatment. - Undergoing treatment with another investigational medication or having been treated with an investigational medication within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment. - Concomitant treatment with strong CYP3A4 inhibitors or inducers. - Receipt of a live vaccine within 30 days of the first dose of study treatment. - Infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week of the first dose of study treatment. - Evidence of HBV or HCV infection or risk of reactivation. - Known history of HIV (HIV 1/2 antibodies). - History of organ transplant, including allogeneic stem-cell transplantation. - Known hypersensitivity or severe reaction to any component of study drug(s) or formulation components. - Presence of a gastrointestinal condition that may affect drug absorption. - Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study. - Any condition that would, in the investigator's judgment, interfere with full participation in the study,pose a significant risk to the participant; or interfere with interpretation of study data |
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques Universitaires Ucl Saint-Luc | Brussels | |
Belgium | Universitaire Ziekenhuis Leuven - Gasthuisberg | Leuven | |
France | Institut Bergonie | Bordeaux | |
France | Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole | Toulouse | |
France | Institut Gustave Roussy | Villejuif | |
Italy | A.O.U. Di Modena - Policlinico | Modena | |
Italy | Istituto Nazionale Tumori Irccs Fondazione Pascale | Naples | |
Italy | Irccs Istituto Clinico Humanitas | Rozzano | |
Italy | Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma) | Verona | |
Spain | Hospital General Universitario Vall D Hebron | Barcelona | |
Spain | Centro Integral Oncologico Clara Campal | Madrid | |
Spain | Fundacion Jimenez Diaz University Hospital | Madrid | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Clinica Universidad de Navarra (Cun) | Pamplona | |
United Kingdom | Cambridge University Hospitals Nhs Foundation Trust | Cambridge | |
United Kingdom | University of Glasgow | Glasgow | |
United Kingdom | Guys and St Thomas Nhs Foundation Trust | London | |
United Kingdom | Imperial College Healthcare Nhs Trust - Hammersmith Hospital | London | |
United Kingdom | The Christie Nhs Foundation Trust Uk | Manchester | |
United States | University of Maryland-Greenebaum Cancer Center | Baltimore | Maryland |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | Md Anderson Cancer Center | Houston | Texas |
United States | Columbia University Medical Center | New York | New York |
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
United States | South Texas Accelerated Research Therapeutics | San Antonio | Texas |
United States | Cedars-Sinai Medical Center | West Hollywood | California |
Lead Sponsor | Collaborator |
---|---|
Incyte Corporation |
United States, Belgium, France, Italy, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of treatment-emergent adverse events (TEAE) | Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug up to 90 days after last dose of study drug. | Up to Approximately 28 months | |
Secondary | Cmax of INCB106385 as a single agent or in combination with INCMGA00012 | Maximum observed plasma concentration. | Up to 6 months | |
Secondary | Tmax of INCB106385 as a single agent or in combination with INCMGA00012 | Time to maximum plasma concentration | Up to 6 months | |
Secondary | Cmin of INCB106385 as a single agent or in combination with INCMGA00012 | Minimum observed plasma concentration over the dose interval | Up to 6 months | |
Secondary | AUC of INCB106385 as a single agent or in combination with INCMGA00012 | Area under the plasma concentration-time curve | Up to 6 months | |
Secondary | CL/F of INCB106385 as a single agent or in combination with INCMGA00012 | Apparent oral dose clearance | Up to 6 months | |
Secondary | Objective Response Rate (ORR) | Defined as the percentage of participants with a best overall response of CR or PR, as determined by investigator radiographic disease assessment according to RECIST v1.1. | Up to approximately 24 months | |
Secondary | Disease Control Rate | Defined as the percentage of participants with a best overall response of CR, PR, or SD, as determined by investigator radiographic disease assessment according to RECIST v1.1. | Up to approximately 24 months | |
Secondary | Duration Of Response (DOR) | Defined as the time from the earliest date of CR or PR until the earliest date of disease progression, as determined by investigator radiographic disease assessment according to RECIST v1.1, or death due to any cause if occurring sooner than progression. | Up to approximately 24 months | |
Secondary | Change in tumoral gene expression | Defined as the percent of patients with change in tumoral targeted gene expression compared to baseline | Predose and Week 5-6 | |
Secondary | Change in immune cell activation in tumors | Defined as the percent of patients demonstrating change in immune cell activation in tumors compared to baseline | Predose and Week 5-6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |